Subject(s)
Acquired Hyperostosis Syndrome , Piperidines , Pyrimidines , Humans , Female , Pregnancy , Pyrimidines/therapeutic use , Pyrimidines/adverse effects , Piperidines/therapeutic use , Adult , Acquired Hyperostosis Syndrome/drug therapy , Acquired Hyperostosis Syndrome/diagnosis , Treatment Outcome , Protein Kinase Inhibitors/therapeutic use , Protein Kinase Inhibitors/adverse effects , Janus Kinase Inhibitors/therapeutic use , Live Birth , Pyrroles/therapeutic use , Pyrroles/adverse effectsSubject(s)
Acquired Hyperostosis Syndrome , Clavicle , Lumbar Vertebrae , Humans , Lumbar Vertebrae/diagnostic imaging , Clavicle/injuries , Clavicle/diagnostic imaging , Acquired Hyperostosis Syndrome/diagnosis , Female , Treatment Outcome , Fractures, Bone/etiology , Fractures, Bone/diagnostic imaging , Middle AgedABSTRACT
Synovitis-acne-pustulosis-hyperostosis-osteomyelitis (SAPHO) syndrome is characterised by aseptic osteitis and is often complicated by pustular dermatitis, such as palmoplantar pustulosis or acne. Although bone lesions are most found in the anterior thoracic region or spine, femoral lesions are not well documented in the literature. There is no established treatment for this condition, and few reports have described its long-term course. Here, we describe two cases of SAPHO syndrome involving the femur and discuss their long-term follow-up. A 40-year-old man (Case 1) presented with right thigh pain. Fifteen years after the initial diagnosis, the pain could be controlled with minomycin, salazosulfapyridine, and methotrexate. X-rays of the femur showed gradual cortical thickening. Although there were waves of pain, it gradually improved with the adjustment of drugs 25 years following the initial diagnosis. A 35-year-old man (Case 2) with right thigh pain was prescribed salazosulfapyridine and methotrexate; however, these were ineffective. Alendronate and guselkumab also proved ineffective. Ultimately, infliximab was started 9 years following disease onset, and pain became manageable. X-rays of the femur showed cortical thickening. SAPHO syndrome can be managed with drug therapies, such as nonsteroidal anti-inflammatory drugs, methotrexate, and conventional synthetic disease-modifying antirheumatic drugs; however, there are occasional treatment-resistant cases.
Subject(s)
Acquired Hyperostosis Syndrome , Femur , Humans , Male , Adult , Acquired Hyperostosis Syndrome/diagnosis , Acquired Hyperostosis Syndrome/complications , Acquired Hyperostosis Syndrome/drug therapy , Femur/pathology , Femur/diagnostic imaging , Treatment Outcome , Methotrexate/therapeutic use , Methotrexate/administration & dosageSubject(s)
Acquired Hyperostosis Syndrome , Pulmonary Arterial Hypertension , Humans , Acquired Hyperostosis Syndrome/diagnosis , Acquired Hyperostosis Syndrome/complications , Acquired Hyperostosis Syndrome/drug therapy , Pulmonary Arterial Hypertension/etiology , Pulmonary Arterial Hypertension/diagnosis , Pulmonary Arterial Hypertension/drug therapy , Pulmonary Arterial Hypertension/physiopathology , Treatment Outcome , Female , Pulmonary Artery/diagnostic imaging , Antihypertensive Agents/therapeutic use , Arterial Pressure/drug effects , Middle AgedSubject(s)
Acquired Hyperostosis Syndrome , Humans , Retrospective Studies , Acquired Hyperostosis Syndrome/drug therapy , Acquired Hyperostosis Syndrome/diagnosis , Acquired Hyperostosis Syndrome/therapy , Female , Male , Treatment Outcome , Adult , Middle Aged , Antirheumatic Agents/therapeutic useABSTRACT
BACKGROUND: SAPHO syndrome is recognized as a rare entity with damage to skin and bones due to inflammation. Currently, the treatment for SAPHO syndrome is still a challenge in clinical practice. In this study, an integrated transcriptomics and network pharmacology approach was applied to explore the therapeutic effect and mechanism of Wang-Bi tablet (WBT) on SAPHO syndrome. METHODS: The main components of WBT and their targets, as well as the targets of SAPHO syndrome, were collected from databases. Network visualization was performed using Cytoscape software. The GO and KEGG enrichment analysis was executed by David dataset. Then, the molecular mechanism of WBT improving SAPHO syndrome was validated by transcriptomics of peripheral blood neutrophils in SAPHO syndrome. Finally, the above results were validated by molecular docking. RESULTS: The Network Pharmacology results showed there are 152 core targets for WBT treatment on SAPHO syndrome. RNA-seq data showed 442 differentially expressed genes (DEGs) in peripheral blood neutrophils of SAPHO patients. Intriguingly, NIK/NF-kappaB-, MyD88-dependent toll-like receptor-, and MAPK pathway were included in the enrichment results of network pharmacology and RNA-seq. Moreover, we verified that the core components of WBT have good affinity with the core targets of NIK/NF-kappaB-, MyD88-dependent toll-like receptor-, and MAPK pathway by molecular docking. CONCLUSIONS: This study illustrated that the possible mechanisms of WBT against SAPHO syndrome may be related to NIK/NF-kappaB-, MyD88-dependent toll-like receptor-, and MAPK pathway, and further experiments are needed to prove these predictions.
Subject(s)
Acquired Hyperostosis Syndrome , Drugs, Chinese Herbal , Humans , Acquired Hyperostosis Syndrome/diagnosis , Acquired Hyperostosis Syndrome/drug therapy , Acquired Hyperostosis Syndrome/genetics , NF-kappa B , Molecular Docking Simulation , Myeloid Differentiation Factor 88 , Network Pharmacology , Gene Expression Profiling , Adaptor Proteins, Signal Transducing , Toll-Like ReceptorsABSTRACT
Synovitis, acne, palmoplantar pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare and refractory autoinflammatory disease, and there is no consensus on its treatment. Stellate ganglion block (SGB) blocks sympathetic nerves, ameliorates immune dysfunction, and alleviates stress response, which has been used to treat various chronic pain syndromes, arrhythmias, and post-traumatic stress disorder (PTSD). Also, the SGB has been reported to be successfully used to treat certain skin diseases, autoinflammatory diseases, and menopausal symptoms. In this study, over 3 years of follow-up, we found that SGB successfully intervened the symptoms of SAPHO syndrome, including sternoclavicular joint arthritis and palmoplantar pustulosis.
Subject(s)
Acquired Hyperostosis Syndrome , Autonomic Nerve Block , Stellate Ganglion , Humans , Acquired Hyperostosis Syndrome/diagnosis , Acquired Hyperostosis Syndrome/therapy , Autonomic Nerve Block/methods , Female , Treatment Outcome , Middle Aged , AdultABSTRACT
INTRODUCTION: The synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare condition. Its treatment remains a challenge for clinicians, and often yields mixed results. CASE: We report the case of a 51-year-old Caucasian woman who presented with SAPHO syndrome with mainly axial involvement. She had been treated with sulfasalazine and anti-inflammatory drugs for many years without any success. A few weeks after starting treatment with tofacitinib, both clinical and biological parameters dramatically improved. Imaging also showed considerable regression of the vertebral and pelvic lesions. However, tofacitinib had to be discontinued due to the occurrence of pulmonary embolism. Consequently, recurrence of bone pain and biologic inflammation was rapidly observed. CONCLUSIONS: Anti-JAKs are an interesting treatment option in the management of SAPHO syndrome that need further clinical trials and assessment for validating response.
Subject(s)
Acne Vulgaris , Acquired Hyperostosis Syndrome , Hyperostosis , Osteitis , Piperidines , Pyrimidines , Synovitis , Female , Humans , Middle Aged , Acquired Hyperostosis Syndrome/diagnosis , Acquired Hyperostosis Syndrome/drug therapySubject(s)
Acquired Hyperostosis Syndrome , Piperidines , Pyrimidines , Pyrroles , Humans , Piperidines/therapeutic use , Pyrimidines/therapeutic use , Acquired Hyperostosis Syndrome/drug therapy , Acquired Hyperostosis Syndrome/diagnosis , Pyrroles/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Female , Treatment Outcome , Middle Aged , Male , AdultSubject(s)
Acquired Hyperostosis Syndrome , Talus , Tarsal Bones , Humans , Talus/diagnostic imaging , Talus/pathology , Acquired Hyperostosis Syndrome/diagnostic imaging , Acquired Hyperostosis Syndrome/diagnosis , Tarsal Bones/diagnostic imaging , Tarsal Bones/pathology , Female , Heel , Middle Aged , Radiography , MaleABSTRACT
OBJECTIVE: The purpose of this study was to describe the distribution of Anterior Chest Wall (ACW) arthropathies in a tertiary care center and identify clinical, biological and imaging findings to differentiate osteoarthritis (OA) from non-osteoarthritis (N-OA) etiologies. METHODS: Search from medical records from January 2009 to April 2022, including patients with manubriosternal and/or sternoclavicular and/or sternocostal joint changes confirmed by ultrasonography, computed tomography or magnetic resonance imaging. The final study group was divided into OA and N-OA subgroups. RESULTS: A total of 108 patients (34 males and 74 females, mean age: 47.3 ± 13 years) were included. Twenty patients had findings of OA, while 88 were diagnosed with N-OA pathologies. SpA was the most common etiology in the N-OA group (n = 75). The other N-OA etiologies were less common: rheumatoid arthritis (n = 4), Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome (n = 3), infectious arthritis (n = 3) and microcrystalline arthropathies (n = 3). Regarding the distinctive features, ACW pain was the inaugural manifestation in 50% of patients in OA group and 18.2% of patients in N-OA group (p = 0.003); high inflammatory biomarkers were more common in N-OA group (p = 0.033). Imaging findings significantly associated with OA included subchondral bone cysts (p < 0.001) and intra-articular vacuum phenomenon (p < 0.001), while the presence of erosions was significantly associated with N-OA arthropathies (p = 0.019). OA was independently predicted by the presence of subchondral bone cysts (p = 0.026). CONCLUSION: ACW pain is a common but often underestimated complaint. Knowledge of the different non-traumatic pathologies and differentiation between OA and N-OA etiologies is fundamental for appropriate therapeutic management.
